MA50120A - Méthodes de traitement à l'aide d'un promédicament d'amphétamine - Google Patents

Méthodes de traitement à l'aide d'un promédicament d'amphétamine

Info

Publication number
MA50120A
MA50120A MA050120A MA50120A MA50120A MA 50120 A MA50120 A MA 50120A MA 050120 A MA050120 A MA 050120A MA 50120 A MA50120 A MA 50120A MA 50120 A MA50120 A MA 50120A
Authority
MA
Morocco
Prior art keywords
treatment
methods
medicinal product
amphetamine pre
amphetamine
Prior art date
Application number
MA050120A
Other languages
English (en)
Inventor
Norman W Barton
Brigitte A Robertson
Original Assignee
Norman W Barton
Brigitte A Robertson
Shire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norman W Barton, Brigitte A Robertson, Shire Pharmaceuticals Inc filed Critical Norman W Barton
Publication of MA50120A publication Critical patent/MA50120A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MA050120A 2017-04-10 2018-04-10 Méthodes de traitement à l'aide d'un promédicament d'amphétamine MA50120A (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762483779P 2017-04-10 2017-04-10
US201762483790P 2017-04-10 2017-04-10
US201762513131P 2017-05-31 2017-05-31
US201762513107P 2017-05-31 2017-05-31
US201762513016P 2017-05-31 2017-05-31
US201762513034P 2017-05-31 2017-05-31

Publications (1)

Publication Number Publication Date
MA50120A true MA50120A (fr) 2020-03-11

Family

ID=63793488

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050120A MA50120A (fr) 2017-04-10 2018-04-10 Méthodes de traitement à l'aide d'un promédicament d'amphétamine

Country Status (7)

Country Link
US (1) US20200155687A1 (fr)
EP (1) EP3618877A4 (fr)
JP (1) JP2020516694A (fr)
CN (1) CN111107878A (fr)
CA (1) CA3059781A1 (fr)
MA (1) MA50120A (fr)
WO (1) WO2018191311A1 (fr)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070099999A1 (en) * 2000-11-01 2007-05-03 Epstein Mel H Methods of treating depression
BR0311503A (pt) * 2002-06-20 2005-02-22 Lundbeck & Co As H Uso de um composto, uso de um agonista parcial, agonista inverso, ou antagonista de receptor de gabab, composição farmacêutica, método para a identificação de compostos úteis para o tratamento de doenças, e, composto
CN101193650A (zh) * 2005-04-08 2008-06-04 新河药品股份有限公司 抗滥用的苯丙胺前体药物
JP2010512413A (ja) * 2006-12-11 2010-04-22 ケムファーム・インコーポレーテッド アンフェタミンの非標準アミノ酸結合体およびそれらの製造方法および使用方法
GB201002612D0 (en) * 2010-02-16 2010-03-31 Jagotec Ag Improvements in or relating to organic compounds
CA2843390A1 (fr) * 2011-07-29 2013-02-07 Kempharm, Inc. Promedicaments de l'homoarginine et/ou conjugues d'amphetamines et d'autres stimulants et leurs procedes de fabrication et d'utilisation
WO2014144115A1 (fr) * 2013-03-15 2014-09-18 Shire Llc Polythérapie à doses prédéterminées pour la schizophrénie
WO2016102530A1 (fr) * 2014-12-22 2016-06-30 Bergen Teknologioverføring As Dérivé d'acide phosphorique cyclique pour le traitement du syndrome de fatigue chronique

Also Published As

Publication number Publication date
CA3059781A1 (fr) 2018-10-18
CN111107878A (zh) 2020-05-05
US20200155687A1 (en) 2020-05-21
JP2020516694A (ja) 2020-06-11
EP3618877A4 (fr) 2021-01-13
WO2018191311A1 (fr) 2018-10-18
EP3618877A1 (fr) 2020-03-11

Similar Documents

Publication Publication Date Title
IL271046A (en) Compounds for treating huntington's disease
MA45192A (fr) Traitement d'association
EP3344274A4 (fr) Méthodes et compositions pour le traitement d'états pathologiques associés à des réponses inflammatoires anormales
ME03070B (fr) Méthodes pour le traitement d'infections virales à filoviridae
IL265528A (en) aav therapy for Huntington's disease
MA46954A (fr) Méthodes de traitement d'états inflammatoires
EP3370721A4 (fr) Traitement de l'ostéoarthrite
EP3668500A4 (fr) Méthodes de traitement de l'arthrose à l'aide d'un gel de cannabidiol transdermique
MA44083A (fr) Composés de biarylmonobactame pour le traitement d'infections bactériennes
EP3340971A4 (fr) Méthodes de traitement de syndrome de lennox-gastaut à l'aide de fenfluramine
EP3291815A4 (fr) Méthodes de traitement d'une maladie neurodégénérative
MA53329A (fr) Méthodes de traitement de l'épilepsie
EP3630102A4 (fr) Formulations pour le traitement d'un trouble de stress post-traumatique
EP3432891A4 (fr) Méthodes de traitement et de prévention d'une infection à c. difficile
EP3362065A4 (fr) Polythérapie pour le traitement de malignités
EP3285776A4 (fr) Méthodes de traitement d'infections bactériennes
EP3386520A4 (fr) Méthodes de traitement d'une maladie ou d'un trouble oculaire
EP3625971A4 (fr) Traitement d'audio spatial
EP3503904A4 (fr) Traitement par ascaroside de l'oesophagite à éosinophiles
EP3419622A4 (fr) Traitement d'une maladie neurodégénérative de l'oeil à l'aide de pridopidine
EP3766497A4 (fr) Médicament pour le traitement de la toux
SI3720433T1 (sl) Bis-holin tetratiomolibdat za zdravljenje Wilsonove bolezni
EP3454793A4 (fr) Bobines de traitement d'anévrisme
EP3393468A4 (fr) Méthodes pour le traitement d'une maladie immunodéficiente
HUE059387T2 (hu) Parkinson-kór kezelése